Innovation spread

What was delivered in 2020-21?

This year, we continued the spread of nationally approved innovations to our colleagues and partners in Wessex, within the context of the pandemic.

"Adam and Joe gave our clinicians significant assistance and expertise throughout this project which has just successfully concluded. Due to their hard work, HHFT Cardiac CT is in a completely different place, compared to where it would have been. This has translated into pathway improvements, better outcomes and reduction in unnecessary invasive testing for our patients, which would not have been possible without AHSN input." 
- Alex Whitfield, chief executive, and Dr Lara Alloway, chief medical officer - Hampshire Hospitals NHS Foundation Trust

AHSN National Lipid Management and Familial Hypercholesterolaemia programme 

Over the next three years, AHSNs will support the NHS to optimise lipid management in people at increased cardiovascular risk. The national AHSN CVD programme will help increase the numbers of those who have their cholesterol measured, and to identify those with conditions that increase familial risk of hypercholesterolaemia.

This is to reduce:

  • the risk for heart attacks and strokes 
  • the risk of admissions and re-admissions associated with cardiovascular disease
  • health inequalities by ensuring a consistent, national approach to lipid management, using a NICE-approved clinical pathway

  • to provide more treatment options to high-risk patients who remain at risk despite maximum tolerated statin therapy.

In Wessex, during 2020-21, we:

  • established working relationships with important CVD stakeholders across the region
  • produced data packs for local CCGs
  • are working with clinicians and commissioners to explore pathway improvements 
  • are linking with our AHSN colleagues across the country to understand what is working well, to assist us in exploring these approaches within Wessex.

Cancer innovations

  • We have supported to apply for the AI in Health and Social Care Awards, for their Red Dot algorithm. 

  • Red Dot analyses chest x-rays, marking appropriate images as either ‘high confidence normal’ or ‘high confidence tumour’. This has potential to reduce radiologist workload, and to speed up the diagnostic pathway for lung cancer by several weeks. 

  • We also helped radiologists from University Hospital Southampton NHS Foundation Trust to join the bid team and provided application and interview support. As a result, UHS will be one of the sites benefiting from the £1.4m grant, and evaluating the impact on patient flow in this critical pathway. 

Our Partners

Back to main annual review